Which lab tests actually matter after 40?
The useful list is shorter—and more individualized—than most checkup packages suggest.
The quick answer
There is no magic ‘40+ panel.’ Start with decisions, not tubes of blood.
For most adults, the highest-value conversation covers cardiovascular risk, diabetes screening, prior HIV and hepatitis C testing, and whether kidney or liver risk factors are present. A standard lipid profile and appropriate glucose testing commonly sit near the center. Other tests become useful only when age, symptoms, history, medications, family risk, or previous results create a clear question.
Usually worth reviewing
A current lipid profile; glucose/A1C screening under local criteria; whether recommended HIV and hepatitis C screening has ever been completed; blood pressure, smoking, family history, weight trajectory, and medications.
Add when risk supports it
Urine albumin and eGFR for kidney risk; liver enzymes and fibrosis assessment for metabolic or liver risk; Lp(a) once in adulthood under the 2026 U.S. guideline; selected thyroid, blood count, iron, B12, or other tests for a defined indication.
Not an automatic checkup
Fasting insulin or HOMA-IR for everyone, broad hormone or micronutrient panels, nonspecific inflammatory markers, and panels of tumor markers in asymptomatic people.
The principleThe right test is the one that answers a defined question and can change what happens next.
MERHI ONE Evidence Map
What is supported—and for whom?
The rating applies to the exact screening claim shown below. It is not a rating of the test in every possible clinical use.
Screen for diabetes from age 35 under guideline-defined criteria.1,2,3
ADA 2026 advises testing no later than 35 for all adults. USPSTF gives a Grade B recommendation for asymptomatic adults 35–70 with overweight or obesity. In Brazil, SBD 2026 recommends universal screening from 35.
Use lipid data as part of adult cardiovascular risk assessment.4,15
The 2026 ACC/AHA guideline integrates cholesterol with age, blood pressure, diabetes, smoking, kidney disease, family history, and other risk enhancers. One isolated LDL-C value is not the entire risk assessment.
Measure Lp(a) at least once in adulthood.4
The 2026 ACC/AHA guideline newly recommends at least one adult Lp(a) measurement. Because levels are largely genetically determined, repeat testing is generally unnecessary unless the clinical situation or assay context changes.
Assess kidney health with both filtration and urine albumin when CKD risk is present.5,6
KDIGO recommends testing people at risk using both GFR assessment and urine albumin. Diabetes, hypertension, cardiovascular disease, obesity, older age, prior kidney injury, and relevant family history can increase risk.
Confirm whether recommended HIV and hepatitis C screening has been completed.7,8,13,14
In the U.S., USPSTF recommends HIV screening for ages 15–65 and HCV screening for ages 18–79, generally once for HCV with repeat testing when ongoing risk exists. Brazilian pathways should follow Ministry of Health testing protocols and personal risk.
Use liver tests and fibrosis assessment when metabolic, medication, alcohol, viral, or other liver risk exists.12
Routine enzymes can support evaluation, but normal ALT or AST does not exclude MASLD or fibrosis. Risk pathways may combine clinical data, routine laboratories, and noninvasive scores.
Screen every asymptomatic adult for thyroid dysfunction solely because they are over 40.9
USPSTF concludes that evidence is insufficient to determine the balance of benefits and harms of universal screening in nonpregnant, asymptomatic adults; its 2024 surveillance found no new evidence requiring an update.
Measure vitamin D in every asymptomatic adult.10
USPSTF concludes that evidence is insufficient to assess the balance of benefits and harms of population screening for vitamin D deficiency in asymptomatic, community-dwelling, nonpregnant adults.
Use broad tumor-marker or multi-cancer blood-test packages as routine screening in average-risk asymptomatic adults.11
NCI notes that CA-125 has not been shown effective as an ovarian-cancer screening test and that the effectiveness of multi-cancer detection blood tests in people without symptoms remains unknown.
Two native pathways
The science is shared. The screening rules are not identical.
United States
- ADA 2026: begin diabetes testing no later than age 35 for all adults.
- USPSTF: screen adults 35–70 with overweight or obesity for prediabetes and type 2 diabetes (Grade B).
- ACC/AHA 2026: use contemporary cardiovascular risk assessment; measure Lp(a) at least once in adulthood.
- USPSTF: HIV screening ages 15–65 and HCV screening ages 18–79, with risk-based testing outside or within these ranges as applicable.
Brazil
- SBD 2026: universal type 2 diabetes screening from age 35, using fasting glucose and/or A1C as initial tests.
- Kidney testing is particularly relevant when diabetes, hypertension, obesity, cardiovascular disease, older age, or other CKD risk is present.
- HIV and viral hepatitis testing should follow Ministry of Health pathways, exposure history, prior testing, and clinical context.
- Terminology, units, access through SUS or private care, and local professional guidance must shape implementation.
Tests that depend on context
Commonly useful does not mean universally necessary.
CBC, ferritin and iron studies
Consider with fatigue, bleeding risk, dietary risk, anemia history, heavy menstrual bleeding, chronic inflammation, gastrointestinal disease, or relevant prior abnormalities.
TSH and free T4
Consider with symptoms, thyroid history, medications, pregnancy-related context, autoimmune risk, examination findings, or previous abnormalities. USPSTF finds evidence insufficient for universal screening of asymptomatic nonpregnant adults.
Vitamin B12, folate and vitamin D
Consider when diet, absorption, medications, bone health, neurologic symptoms, anemia patterns, or other risk factors create a question. USPSTF finds evidence insufficient for population screening for vitamin D deficiency in asymptomatic adults.
Liver enzymes and fibrosis pathways
Consider with obesity, diabetes, dyslipidemia, alcohol exposure, hepatotoxic medications, viral hepatitis risk, family history, or abnormal imaging or prior tests.
ApoB
The 2026 ACC/AHA guideline supports selective use to assess residual risk, particularly in cardiometabolic disease, diabetes, high triglycerides, known cardiovascular disease, or discordant lipid results.
Low-value blanket testing
More results can create more noise—not necessarily more health.
These tests can be valuable for selected clinical questions. The concern is ordering them routinely for every asymptomatic adult simply because they turned 40.
Fasting insulin and HOMA-IR for everyone
They may be used in research or selected clinical contexts, but major diabetes diagnostic guidelines rely on glucose, A1C, and oral glucose tolerance tests—not a universal insulin-resistance cutoff.
Expanded thyroid panels without a question
Free T3, reverse T3, and thyroid antibodies do not belong automatically in every preventive panel.
Broad vitamin and mineral panels
Assay limitations, low pretest probability, supplement use, and uncertain clinical consequences can make isolated abnormalities difficult to interpret.
CRP, ESR, fibrinogen, and ‘inflammation panels’
Nonspecific markers do not reveal the cause of inflammation and should not be marketed as a complete health score.
Tumor-marker packages
Tests such as CA-125 and many multi-cancer blood tests have not been shown to be effective general screening tools in asymptomatic average-risk adults. They must not replace recommended cancer screening.
Potential harms of indiscriminate panels
- False-positive or borderline results
- Unnecessary repeat tests and imaging
- Anxiety and diagnostic labels without proven benefit
- Incidental findings and treatment cascades
- False reassurance from a normal panel
- Cost without a clear decision benefit
A better 40+ checkup conversation
Bring questions, history, and prior results—not a shopping list.
- 01
Review personal and family history, symptoms, medications, supplements, blood pressure, weight trend, smoking, sleep, and activity.
- 02
Ask which preventive screenings are due—not only blood tests. Colorectal, breast, cervical, lung, prostate, bone, and vaccination decisions follow separate age- and risk-based pathways.
- 03
Identify the decision each proposed laboratory test is expected to influence.
- 04
Compare with prior results and confirm unexpected abnormalities when appropriate before assigning a diagnosis.
- 05
Agree on follow-up timing based on the result, baseline risk, and guideline—not a fixed annual bundle for everyone.
Frequently asked
Short answers to common questions.
Does a result inside the reference range prove I am healthy?+
No. Reference intervals describe a laboratory population and method. Risk thresholds, diagnostic criteria, treatment targets, symptoms, and trends may use different concepts.
Do all blood tests require fasting?+
No. Fasting depends on the test and clinical question. Fasting glucose requires a defined fasting state; many lipid assessments can be performed without fasting, while very high triglycerides or specific questions may change preparation.
Should every test be repeated every year?+
No. Frequency depends on baseline risk, prior findings, treatment, age, and the specific guideline. Some tests may be one-time; others require shorter or longer intervals.
Can a comprehensive panel detect most cancers?+
No. A normal panel does not rule out cancer. Use proven cancer-screening pathways rather than nonspecific tumor-marker bundles.
Can I use this article to order my own tests?+
It is designed to improve a clinical conversation, not replace one. Individual risks, symptoms, medications, and prior results can make a very different list appropriate.
Claim-level foundation
References
Priority was given to current guidelines, systematic evidence reviews, and official sources. Each evidence-map statement points to the references that support it.
- 01Open source ↗
American Diabetes Association · 2026
Standards of Care in Diabetes — Diagnosis and Classification
- 02Open source ↗
U.S. Preventive Services Task Force · 2021
Prediabetes and Type 2 Diabetes: Screening
- 03Open source ↗
Sociedade Brasileira de Diabetes · 2026
Diagnosis of diabetes mellitus — Brazilian guideline
- 04Open source ↗
ACC / AHA / Multisociety · 2026
Guideline for the Management of Dyslipidemia
- 05Open source ↗
KDIGO · 2024
Clinical Practice Guideline for the Evaluation and Management of CKD
- 06Open source ↗
Ministério da Saúde / Conitec · 2024
Brazilian clinical protocol for chronic kidney disease
- 07Open source ↗
U.S. Preventive Services Task Force · 2019
HIV Infection: Screening
- 08Open source ↗
U.S. Preventive Services Task Force · 2020
Hepatitis C Virus Infection: Screening
- 09Open source ↗
U.S. Preventive Services Task Force · 2015; surveillance 2024
Thyroid Dysfunction: Screening
- 10Open source ↗
U.S. Preventive Services Task Force · 2021
Vitamin D Deficiency in Adults: Screening
- 11Open source ↗
National Cancer Institute · 2024
What Cancer Screening Tests Check for Cancer?
- 12Open source ↗
American Association for the Study of Liver Diseases · Current guidance
Practice Guidelines and noninvasive liver disease assessment
- 13Open source ↗
Ministério da Saúde · Updated 2026
Brazilian clinical protocols for HIV and sexually transmitted infections
- 14Open source ↗
Ministério da Saúde · Updated 2026
Brazilian clinical protocol for hepatitis C
- 15Open source ↗
American College of Cardiology · Guideline tool
Lipid Manager — fasting and nonfasting lipid measurement
Editorial record